Year None20232022202120202019201820172016 09-26-2023 Pliant Therapeutics Announces Positive Safety and Exploratory Efficacy Data from Phase 2a INTEGRIS-PSC Clinical Trial of Bexotegrast in Patients with Primary Sclerosing Cholangitis and Suspected Liver Fibrosis 09-25-2023 Pliant Therapeutics to Host Investor Call and Webcast to Discuss Interim Results from INTEGRIS-PSC, a Phase 2a Trial in Patients with Primary Sclerosing Cholangitis 09-15-2023 Pliant Therapeutics Appoints Minnie Kuo as Chief Development Officer 09-11-2023 Pliant Therapeutics Announces Presentations at the European Respiratory Society International Congress 2023 08-30-2023 Pliant Therapeutics to Participate in Upcoming Investor Conferences 08-28-2023 Pliant Therapeutics Announces Three Upcoming Presentations at the European Respiratory Society International Congress 2023 08-09-2023 Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2023 Financial Results 08-09-2023 Pliant Therapeutics Announces Initiation of BEACON-IPF, a Phase 2b Clinical Trial of Bexotegrast in Idiopathic Pulmonary Fibrosis 07-25-2023 Pliant Therapeutics to Participate in Upcoming Investor Conferences 06-23-2023 Pliant Therapeutics Presents Data from its Bexotegrast Program at the European Association for the Study of the Liver (EASL) International Liver Congress™ Pagination Current page 1 Page 2 Page 3 Next page next › Last page last »